$85.00Original price was: $85.00.$66.00Current price is: $66.00.
PT-141, also called Bremelanotide (generic clinical name), is a heavily modified synthetic derivative of alpha-melanocyte-stimulating hormone. It has been tested in clinical trials as a treatment for both male/female hypoactive sexual desire disorder and acute hemorrhage. PT-141 is an agonist for the melanocortin-4 and melanocortin-1 receptors. Research shows that it promotes sexual arousal and stimulates the immune system.
PT-141 (Bremelanotide) is typically administered 30 to 60 minutes before desired effect, as needed. A common starting dose is 1.25 mg (1.25 ml) via subcutaneous injection. Based on individual tolerance and efficacy, the dose may be increased to 1.75 mg (1.75 ml). Maximum recommended usage is no more than 8 mg per month, with at least 72 hours between doses.
For those new to PT-141, dosing should follow a titration schedule:
Week 1: Begin with 0.5 mg (0.5 ml) to assess sensitivity
Week 2–3: Increase to 1 mg (1 ml), 30–60 minutes prior to anticipated effect
Week 4 onward: Use 1–1.75 mg (1–1.75 ml) as needed, with a minimum 3-day interval between doses
Injection should be subcutaneous, preferably in the abdomen or thigh. Effects typically begin within 30–60 minutes and may last up to 6–12 hours, with variability between individuals.
Each 10ml vial provides:
10 doses at 1 mg
~5–6 doses at 1.75 mg
Up to 20 half-doses (0.5 mg) for conservative use or titration
PT-141 (Bremelanotide) is a synthetic peptide derived from melanocortin analogs. Unlike traditional sexual function agents that work through the vascular system (e.g., PDE5 inhibitors), PT-141 directly activates the melanocortin-4 receptor (MC4R) in the central nervous system, stimulating arousal pathways in the brain.
Initially developed as a tanning agent, PT-141 was found to induce sexual desire and response in both men and women. It is clinically studied for hypoactive sexual desire disorder (HSDD) and has been FDA-approved (as Vyleesi®) for this condition in premenopausal women.
Its effects are neurological rather than vascular, making it effective even in individuals who do not respond to traditional erectile dysfunction treatments.
PT-141 is a melanocortin receptor agonist, acting primarily on the MC4R and MC3R located in the hypothalamus. It enhances sexual behavior and desire by activating central arousal pathways.
Key pharmacological actions:
Stimulates dopaminergic and melanocortin neural circuits
Enhances libido and sexual responsiveness in both sexes
Bypasses the nitric oxide pathway — effective even when PDE5 inhibitors are not
Minimal peripheral effects on blood flow compared to sildenafil or tadalafil
This makes PT-141 a unique therapeutic option for addressing low sexual desire in both men and women.
PT-141 has not been studied extensively in pregnant or breastfeeding individuals and should be avoided during these periods. While preclinical data show minimal reproductive toxicity, its effects on fetal development or milk production are unknown.
PT-141 is strictly contraindicated in pediatric populations. It is a CNS-active sexual arousal agent and is inappropriate for use in anyone under the age of 18.
PT-141 (Bremelanotide) has been FDA-approved under the trade name Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
However, compounded formulations such as injectables are not FDA-approved for general or off-label use in other populations. Compounding pharmacies may produce PT-141 in injectable form under regulatory guidelines.
